


Supplementary Materials


- **Supplementary Figure S1.** Morphology of OS PDC lines and Alizarin Red staining. These are anonymised samples of patients diagnosed with osteosarcoma by tumour biopsy. They are a mix of both sexes and come from patients between the ages of 12 to 68. **(a)** Morphology of cell lines at 75%-90% confluence. 4x magnification. **(b)** Alizarin red assays were performed to assess mineralization of OS PDC lines. 40x magnification. **(c)** negative control for Alizarin Red staining.
- **Supplementary Figure S2.** Whole Western Blots of OS cell lines for non-phosphor (active) β -catenin, total β -catenin, Wntless, and housekeeping protein GAPDH.
- **Supplementary Figure S3.** Tumour volume growth curves and final tumour weights for SJSA-1 (a, b) and 143B xenografts (c, d).
- **Supplementary Figure S4.** IHC for β -catenin on SJSA-1 xenograft sections. Mice were treated with either **(a)** vehicle or **(b)** ETC-159. The ETC-159 treatment set showed greatly reduced β -catenin staining intensity as compared to the control group. Images were captured at 20x and 40x as indicated.

Supplementary Figure S1. PDC photomicrographs and Alizarin red staining


a




OS008




OS022



OS023




OS024




KEN02


b




OS008




OS022



OS023



OS024




KEN02

c




Negative control

Supplementary Figure S2. Whole Western blots of OS cell lines




Supplementary Figure S3. Tumour growth curves and final weights



Supplementary Figure S4. IHC for β -catenin in SJSA-1 Vehicle / Treated xenografts

a



b

